It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The cell division cycle 25 phosphatases CDC25A, B and C regulate cell cycle transitions by dephosphorylating residues in the conserved glycine-rich loop of CDKs to activate their activity. Here, we present the cryo-EM structure of CDK2-cyclin A in complex with CDC25A at 2.7 Å resolution, providing a detailed structural analysis of the overall complex architecture and key protein-protein interactions that underpin this 86 kDa complex. We further identify a CDC25A C-terminal helix that is critical for complex formation. Sequence conservation analysis suggests CDK1/2-cyclin A, CDK1-cyclin B and CDK2/3-cyclin E are suitable binding partners for CDC25A, whilst CDK4/6-cyclin D complexes appear unlikely substrates. A comparative structural analysis of CDK-containing complexes also confirms the functional importance of the conserved CDK1/2 GDSEID motif. This structure improves our understanding of the roles of CDC25 phosphatases in CDK regulation and may inform the development of CDC25-targeting anticancer strategies.
CDC25 phosphatases are attractive anticancer drug targets that regulate CDK activity. Here, the authors present the cryo-EM structure of the CDK2-cyclin A-CDC25A complex at 2.7 Å resolution, detailing key protein-protein interactions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Framlington Place, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Paul O’Gorman Building, Newcastle upon Tyne, UK (GRID:grid.1006.7) (ISNI:0000 0001 0462 7212)
2 Framlington Place, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Paul O’Gorman Building, Newcastle upon Tyne, UK (GRID:grid.1006.7) (ISNI:0000 0001 0462 7212); Stockton-on-Tees, Fujifilm, Belasis Ave, Billingham, UK (GRID:grid.434589.7) (ISNI:0000 0004 4662 2622)
3 Framlington Place, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Paul O’Gorman Building, Newcastle upon Tyne, UK (GRID:grid.1006.7) (ISNI:0000 0001 0462 7212); Milton, Evotec (UK) Ltd., Abingdon, UK (GRID:grid.448222.a) (ISNI:0000 0004 0603 4164)
4 University of Leeds, Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Leeds, UK (GRID:grid.9909.9) (ISNI:0000 0004 1936 8403)
5 Heslington, York Structural Biology Laboratory and York Biomedical Research Institute, Department of Chemistry, University of York, York, UK (GRID:grid.5685.e) (ISNI:0000 0004 1936 9668)